Elanco Animal Health (NYSE:ELAN) Trading Down 4.5% – Should You Sell?

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) traded down 4.5% during trading on Tuesday . The stock traded as low as $20.68 and last traded at $20.7090. 4,921,180 shares traded hands during trading, a decline of 16% from the average session volume of 5,833,618 shares. The stock had previously closed at $21.69.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ELAN shares. JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $18.00 to $24.00 in a report on Tuesday, October 7th. Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th. UBS Group lifted their target price on Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Stifel Nicolaus boosted their price target on Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Finally, Piper Sandler raised their price objective on Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $22.78.

Elanco Animal Health Trading Down 3.6%

The firm has a fifty day moving average of $21.69 and a 200-day moving average of $17.87. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. The stock has a market capitalization of $10.39 billion, a price-to-earnings ratio of 348.31, a P/E/G ratio of 2.97 and a beta of 1.86.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the prior year, the business earned $0.13 earnings per share. The company’s revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, equities analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Institutional investors and hedge funds have recently made changes to their positions in the company. Nuveen LLC bought a new position in shares of Elanco Animal Health in the 1st quarter worth about $115,212,000. UBS Group AG raised its stake in Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after acquiring an additional 5,961,457 shares during the period. Dimensional Fund Advisors LP boosted its stake in Elanco Animal Health by 14.3% in the first quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company’s stock valued at $214,875,000 after acquiring an additional 2,563,740 shares during the period. Jennison Associates LLC lifted its holdings in shares of Elanco Animal Health by 322.0% in the 2nd quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock worth $46,192,000 after purchasing an additional 2,468,122 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after purchasing an additional 2,445,872 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.